Physician profile

L Smith

Vineland, NJ

NPI 1487696407

$346.28

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$29.44

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Genentech USA, INC. $82.82 2019-2021
Lilly USA, LLC $70.07 2020-2021
Novartis Pharmaceuticals Corporation $54.30 2021-2023
Leo Pharma INC. $40.50 2020-2022
Karl Storz Endoscopy-America $18.99 2022
E.R. Squibb & Sons, L.L.C. $15.61 2023 Sotyktu
Epi Health, LLC $14.92 2020
Incyte Corporation $13.56 2022
Medtronic, INC. $12.86 2022
Amgen INC. $12.24 2019
Biofrontera INC. $10.41 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

L Smith

$346.28

in general payments reported 2019-2025

Years
2019-2023
Top company
Genentech USA, INC.

https://glasscript.com/doctor/158414/l-smith

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.